US EditionASCENT-03 Trial Supports Standard Use of Sacituzumab Govitecan in mTNBC
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.9 Articles
9 Articles
Drug-antibody conjugated drugs (ADCs), known as "Trojan Horses", are more effective than conventional chemotherapy to treat metastatic breast cancer. For the first time, they have become the new standard of first-line treatment in metastatic triple negative breast cancer rather than chemotherapy, so far first-choice treatment, as concluded by the international clinical trial ASCENT-03.
ASCENT-03 Trial Demonstrates Efficacy of Sacituzumab Govitecan for Advanced Triple-Negative Breast Cancer Patients
Researchers have reported significant findings from the […] The post ASCENT-03 Trial Demonstrates Efficacy of Sacituzumab Govitecan for Advanced Triple-Negative Breast Cancer Patients first appeared on GeneOnline News. The post ASCENT-03 Trial Demonstrates Efficacy of Sacituzumab Govitecan for Advanced Triple-Negative Breast Cancer Patients appeared first on GeneOnline News.
A clinical trial has reinforced as a therapeutic option drug-antibody conjugated drugs (ADCs), which act as a Trojan horse and are more effective than conventional chemotherapy to treat metastatic breast cancer.These are the conclusions of the international clinical trial ASCENT-03, led by the IBCC-Pangaea Oncology, at the Oncology Institute Chirónsalud Teknon in Barcelona, and the IOB Madrid, and published on Sunday The New England Journal of M…
A clinical trial has reinforced as a therapeutic option drug-antibody conjugated drugs (ADCs), which act as a Trojan horse and are more effective than conventional chemotherapy to treat metastatic breast cancer. These are the conclusions of the international clinical trial ASCENT-03, led by the IBCC-Pangaea Oncology, at the Oncology Institute Chirónsalud Teknon in Barcelona, and the IOB Madrid, and published on Sunday The New England Journal of …
Coverage Details
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
